ClinicalTrials.Veeva

Menu

Study of Aripiprazole in the Treatment of Children and Adolescents With Autistic Disorder (AD)

Otsuka logo

Otsuka

Status and phase

Completed
Phase 3

Conditions

Autistic Disorder
Behavioral Symptoms

Treatments

Drug: Aripiprazole
Drug: Placebo

Study type

Interventional

Funder types

Industry

Identifiers

NCT00337571
CN138-179

Details and patient eligibility

About

This study will compare the effectiveness (how well the drug works) of aripiprazole with placebo (fixed dose) in reducing serious behavioral problems in children and adolescents with a diagnosis of autistic disorder (AD).

Enrollment

218 patients

Sex

All

Ages

6 to 17 years old

Volunteers

No Healthy Volunteers

Inclusion criteria

  • Meets current Diagnostic and Statistical Manual of Mental Disorders, Fourth Edition, Text Revision (DSM-IV-TR) diagnostic criteria for AD and demonstrates serious behavioral problems; diagnosis confirmed by Autism, Diagnostic Interview-Revised (ADI-R).
  • CGI score > = 4 AND an ABC Irritability/Agitation subscale score > = 18 at screening and baseline (randomization)
  • Mental age of at least 18 months
  • Male or female 6 to 17 years of age inclusive, at the time of randomization

Exclusion criteria

  • Patients considered treatment resistant to neuroleptic medication based on lack of therapeutic response to 2 different neuroleptics after treatment of at least 3 weeks each
  • Patients previously treated and not responding to aripiprazole treatment
  • The patient is currently diagnosed with another disorder on the autism spectrum, including PDD-NOS, Asperger's Disorder, Rett's Disorder, Fragile-X Syndrome or Childhood Disintegrative Disorder
  • Current diagnosis of bipolar disorder, psychosis, schizophrenia, or major depression
  • A seizure in the past year
  • History of severe head trauma or stroke
  • Non-pharmacologic therapy (e.g., psychotherapy, behavior modification) should be stable prior to screening and consistent throughout the study

Trial design

Primary purpose

Treatment

Allocation

Randomized

Interventional model

Parallel Assignment

Masking

Double Blind

218 participants in 4 patient groups, including a placebo group

A1
Experimental group
Description:
5 mg
Treatment:
Drug: Aripiprazole
A2
Experimental group
Description:
10 mg
Treatment:
Drug: Aripiprazole
A3
Experimental group
Description:
15 mg
Treatment:
Drug: Aripiprazole
B1
Placebo Comparator group
Treatment:
Drug: Placebo

Trial contacts and locations

31

Loading...

Data sourced from clinicaltrials.gov

Clinical trials

Find clinical trialsTrials by location
© Copyright 2024 Veeva Systems